Trials / Completed
CompletedNCT01622777
The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study
Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Effect of Rosuvastatin in Diabetic Polyneuropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Alejandra Guillermina Miranda Diaz · Academic / Other
- Sex
- All
- Age
- 35 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the impact of oral rosuvastatin in diabetic polyneuropathy, and the role of lipid peroxidation and nerve growth factor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin | 20 mg daily of oral rosuvastatin for 12 weeks |
| DRUG | Placebo | 100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2011-01-01
- Completion
- 2011-06-01
- First posted
- 2012-06-19
- Last updated
- 2012-06-20
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT01622777. Inclusion in this directory is not an endorsement.